Enlivex Announces Pre-Print Publication of Total Final results from Phase Ib Critical Sepsis Trial on medRxiv

– Comparison of 10 AllocetraTM-taken care of sufferers with 37 matched controls showed significant constructive responses in condition of organ failure, period of ICU stay and mortality in a really fragile and extremely tricky to address populace with serious sepsis –

Nes Ziona, Israel, Dec. 21, 2020 (Globe NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-phase immunotherapy corporation, right now declared the pre-print publication of a manuscript titled “Apoptotic cells for therapeutic use in cytokine storm affiliated with sepsis,” on medRxiv.org. The pre-print manuscript offers beneficial safety and efficacy knowledge from a finished Stage Ib investigator-initiated clinical trial evaluating AllocetraTM in individuals with serious sepsis. The comprehensive manuscript can be accessed working with the adhering to link: https://www.medrxiv.org/information/10.1101/2020.12.03.20242586v1.

The key goal of the Period Ib trial was to ascertain the protection profile and tolerability of AllocetraTM. In addition, the trial measured the consequences of AllocetraTM procedure on mortality, organ dysfunction and size of intense treatment unit (ICU) and hospitalization remain.

The closing evaluation from the demo in comparison scientific facts from 10 AllocetraTM-taken care of patients admitted to the ICU with intense sepsis with 37 matched controls who been given only standard of care treatment at the same healthcare facility from 2014-2019. Handle patients were matched by age, gender, Sequential Organ Failure Evaluation (Couch) score, and infection supply. The medical demo was done at Hadassah Clinical Centre, which is one of the greatest and most prestigious hospitals in Israel. 

Key facts and conclusions from the scientific demo contain:


The Acute Physiology and Continual Health Evaluation (APACHEII) score of the AllocetraTM-treated team was 12.9, and the corresponding likelihood of mortality of at minimum just one individual in that group was predicted at 85% dependent on the clinic ICU staff’s scientific evaluation of that patient’s general ailment at admission. Even so, none (%) of the AllocetraTM-treated individuals died all through the 28-working day analyze time period, as as opposed to 27% mortality in the matched command group in the course of the exact 28-day period of time.

Sepsis & Organ Failure

Every single of the 10 AllocetraTM-dealt with sufferers experienced concerning 2 to 5 dysfunctional organ techniques upon admission to the ICU. All (100%) of the AllocetraTM-handled clients had swift and total recovery from their septic disorders and any organ dysfunction that was present upon admission to the ICU. Inspite of the equivalent Couch rating at admission between the AllocetraTM-addressed sufferers and the matched controls (regular of 3.4 versus 3.47), no AllocetraTM-addressed clients experienced an maximize in organ-failure state article AllocetraTM remedy, whilst the greater part of matched controls had an boost in organ-failure condition. The average worsening in organ-failure point out of people in the matched handle team was about 100% when compared with their original ICU hospitalization point out vs % % worsening in the organ-failure condition of AllocetraTM-dealt with individuals soon after cure (p<0.0001).

Duration of ICU Hospitalization

The ICU length-of-stay for all AllocetraTM-treated patients was significantly shorter than those patients who received only the standard of care, with an average of 4.7 days compared to 11.1 days in the matched controls group, a 58% reduction (p<0.0001). The slowest ICU discharge of a patient treated with AllocetraTM was after 8 days, while approximately 50% of the matched controls group remained in the ICU after 21 days.

Cytokines/Chemokines/ Immune Modulators/Stress Factors

As expected in the case of sepsis, most of the AllocetraTM-treated patients had elevated pro-, and anti-inflammatory cytokines/chemokines/immune modulators/stress factors, with a gradual normalization upon resolution of sepsis in the patients.


AllocetraTM was shown to be safe and tolerable, with no serious adverse events.

Prof. Dror Mevorach, Chief Medical Officer of Enlivex, commented, “We were excited to observe such deep and durable responses at a well-tolerated dose in this highly fragile and extremely difficult to treat septic population, and to obtain statistically-significant differences from the matched control group. We believe these data highlight the potential of AllocetraTM as a treatment for sepsis, which is a clinical condition that currently has no effective therapies and poor clinical outcomes.”
Oren Hershkovitz, Chief Executive Officer of Enlivex, stated, “The robust results of this study are highly encouraging, and we are pleased that they are now available for detailed review on medRxiv. These results, taken together with final and interim results from Phase Ib and Phase II trials evaluating AllocetraTM in severe and critical  COVID-19 patients, suggest that AllocetraTM has the potential to be effective in multiple clinical indications whose pathophysiologies are associated with cytokine storms and exaggerated immune responses.”


The aim of this study was to determine the safety, tolerability and efficacy of AllocetraTM in subjects admitted to the ICU with sepsis. AllocetraTM (140×106 cells/kg) was administered in either a single dose to 6 patients at day 1 or in two doses to 4 additional patients at days 1 and 3,. Patients were followed for 28 days. The study subjects were also compared to historical controls hospitalized in the ICU, matched by age, gender, SOFA score, and infection source.


Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated immune response to infection. Sepsis has been identified by the World Health Organization as a global health priority and currently has no FDA-approved pharmacologic treatment. Sepsis is the third leading cause of mortality in the United States after cardiovascular disease and cancer and affects approximately 1.7 million adults in the United States each year. Various studies have estimated that up to 50% of severe sepsis hospitalizations culminate in death.


AllocetraTM has been designed to provide a novel immunotherapy mechanism of action that targets life-threatening clinical indications that are defined as “unmet medical needs”, including organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumor microenvironment.


Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies. For more information, visit  http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications that ongoing studies may not continue to show substantial or any activity and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT                                                                            
Shachar Shlosberger, CFO                                                                    
Enlivex Therapeutics, Ltd.                                                                      
[email protected]

Eric Ribner
LifeSci Advisors
[email protected]